Literature DB >> 11004306

Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.

T W Stone1, G J Jaffe.   

Abstract

PURPOSE: To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen.
METHODS: Case reports.
RESULTS: A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped.
CONCLUSION: Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004306     DOI: 10.1016/s0002-9394(00)00495-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

Review 1.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Enhanced activity of antisense phosphorothioate oligos against leishmania amastigotes: augmented uptake of oligo, ribonuclease H activation, and efficient target intervention under altered growth conditions.

Authors:  M Mishra; J M Porter-Kelley; P K Singh; J R Bennett; G Chaudhuri
Journal:  Biochem Pharmacol       Date:  2001-09-01       Impact factor: 5.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.